Peptide YY and cancer: current findings and potential clinical applications

  title={Peptide YY and cancer: current findings and potential clinical applications},
  author={William W Tseng and Carson D. Liu},
Expression and function of dipeptidyl peptidase IV and related enzymes in cancer.
In contrast to proteases involved in cancer development and progression as the executors of tissue degradation, most DASH operate as regulatory molecules, modifying biologically active peptides, which has been observed in the microenvironment of numerous malignancies.
Expression of peptide YY by human blood leukocytes
Serial Plasma Concentrations of PYY and Ghrelin During Chemotherapy in Children With Acute Lymphoblastic Leukemia
PYY and ghrelin play a major role in pathogenesis of anorexia-cachexia syndrome in pediatric ALL patients and are correlated with body mass index and leukemic burden.
PYY-Tag Transgenic Mice Displaying Abnormal (H+-K+)ATPase Activity and Gastric Mucosal Barrier Impairment
The abnormal and unregulated levels of circulating peptide YY and glucagon led to gastric acid inhibition and an impairment of gastric barrier function as a result of a striking reduction in epithelial proliferation.
Identification and verification of HCAR3 and INSL5 as new potential therapeutic targets of colorectal cancer
10 key hub genes associated with CRC were presented and HCAR3 and INSL5 were expressed in tumor tissue and these were associated with poor survival and warrant further studies as potential therapeutic targets.


Peptide YY inhibits growth of human breast cancer in vitro and in vivo.
Peptide YY inhibits growth of breast cancer in vitro and in vivo and may be of benefit in the treatment of this malignancy.
Peptide YY and vitamin E inhibit hormone-sensitive and -insensitive breast cancer cells.
It is shown that peptide YY, an endogenous gut hormone, and vitamin E succinate (VES) inhibit pancreatic cancer cell growth in vitro and that when used in combination, the agents have a significant increase in effect.
Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth.
PYY and vitamin E both inhibit growth of pancreatic cancer cells in vitro with a significant increase in effect when used in combination with a dramatic additive inhibition of growth.
Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1.
A significant reduction in human ductal pancreatic cancer growth is revealed when treated with either PYY or its analog, BIM-43004-1, which may be useful hormonal adjuncts in the chemotherapy of pancreatic adenocarcinoma.
Cancer anorexia-cachexia syndrome: are neuropeptides the key?
  • A. Inui
  • Biology, Medicine
    Cancer research
  • 1999
Although therapeutic intervention using neuropeptide agonists/antagonists is now directed at obesity treatment, it may also have an effect on treating cancer anorexia-cachexia, especially when combined with other agents that have effects on muscle and protein breakdown.
How Age Changes the Content of Neuroendocrine Peptides in the Murine Gastrointestinal Tract
The changes in neuroendocrine peptides observed in the gastrointestinal tract of this murine animal model could be of some relevance for the increased gastrointestinal dysfunction in the elderly human.